Rep. Greg Landsman Sells Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares

Representative Greg Landsman (D-Ohio) recently sold shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). In a filing disclosed on November 14th, the Representative disclosed that they had sold between $1,001 and $15,000 in Regeneron Pharmaceuticals stock on October 15th. The trade occurred in the Representative’s “SARAH LANDSMAN TRADITIONAL IRA” account.

Representative Greg Landsman also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Pfizer (NYSE:PFE) on 10/15/2024.
• Sold $1,001 – $15,000 in shares of Cheniere Energy (NYSE:LNG) on 10/15/2024.
• Sold $15,001 – $50,000 in shares of Phillips 66 (NYSE:PSX) on 10/15/2024.
• Sold $15,001 – $50,000 in shares of Diamondback Energy (NASDAQ:FANG) on 10/15/2024.
• Sold $1,001 – $15,000 in shares of NextEra Energy (NYSE:NEE) on 10/15/2024.
• Sold $1,001 – $15,000 in shares of Linde (NASDAQ:LIN) on 10/15/2024.
• Sold $1,001 – $15,000 in shares of CrowdStrike (NASDAQ:CRWD) on 10/15/2024.
• Sold $15,001 – $50,000 in shares of Exxon Mobil (NYSE:XOM) on 10/15/2024.
• Sold $15,001 – $50,000 in shares of Amazon.com (NASDAQ:AMZN) on 10/15/2024.
• Purchased $1,001 – $15,000 in shares of NextEra Energy (NYSE:NEE) on 9/10/2024.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $756.81 on Friday. The business has a 50 day simple moving average of $992.70 and a 200-day simple moving average of $1,033.92. Regeneron Pharmaceuticals, Inc. has a 12 month low of $753.69 and a 12 month high of $1,211.20. The stock has a market capitalization of $83.17 billion, a PE ratio of 18.93, a price-to-earnings-growth ratio of 3.04 and a beta of 0.15. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of large investors have recently modified their holdings of REGN. Rakuten Securities Inc. grew its stake in shares of Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 19 shares in the last quarter. Stephens Consulting LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter worth approximately $26,000. Sachetta LLC grew its position in shares of Regeneron Pharmaceuticals by 71.4% in the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 10 shares in the last quarter. FSA Wealth Management LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth approximately $26,000. Finally, Crewe Advisors LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter worth approximately $28,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. The trade was a 27.07 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 7.48% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several analysts have weighed in on REGN shares. Oppenheimer lowered their target price on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. Cantor Fitzgerald reissued a “neutral” rating and issued a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. Guggenheim upped their target price on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a report on Friday, August 2nd. Leerink Partners reissued a “market perform” rating and issued a $1,077.00 target price (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. Finally, Evercore ISI decreased their price objective on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. One analyst has rated the stock with a sell rating, four have given a hold rating and nineteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,099.55.

About Representative Landsman

Greg Landsman (Democratic Party) is a member of the U.S. House, representing Ohio’s 1st Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2025. Landsman is also a member of the Cincinnati City Council in Ohio. He assumed office on January 2, 2018. His current term ends on January 1, 2024. Landsman (Democratic Party) is running for re-election to the U.S. House to represent Ohio’s 1st Congressional District. He declared candidacy for the 2024 election. Greg Landsman was born in Cincinnati, Ohio, and lives in Mt. Washington, Ohio. Landsman earned a B.A. in economics and political science from Ohio University and an M.A. in theological studies, religion, and public policy from Harvard University in 2004. His career experience includes working as the executive director of The Strive Partnership with the KnowledgeWorks Foundation and the director of the Ohio Governor’s Office of Faith-Based and Community Initiatives.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.